Intracellular delivery III : market entry barriers of nanomedicines /: market entry barriers of nanomedicines. (2016)

• Record Type: Book
• Further Information: Note: Aleš Prokop, Volkmar Weissig, editors.
• Editors: Prokop, Aleš; Weissig, Volkmar
• Contents: Contributors; Introduction to Volume III; Part I: Introductory Chapters; Chapter 1: Overview of Present Problems Facing Commercialization of Nanomedicines; 1.1 Introduction; 1.2 Extracellular Matrix Manipulation; 1.3 Extending the Blood Nanoparticle Circulation; 1.4 Passive and Active Targeting; 1.5 Differences Between Man and Mice; 1.6 Cell-Specific Targeting; 1.7 Subcellular Organelle-Targeted Drug Delivery; 1.8 Towards the Improved Imaging Technique in Humans; 1.9 New Quantitative Tools to Explore Pharmacokinetics. 1.10 How can Academia Survive With Diminishing Funding and How it Affects Nanomedicine Patenting?; 1.11 Analysis of Present Market Push; Web Citations and References; Web Citations; References; Chapter 2: Precision Drugs and Cell-Specific Drug Delivery; 2.1 Introduction; 2.2 Precision Drugs; 2.3 Antibodies; 2.4 Tumor Antigens; 2.4.1 Tumor-Associated Antigens; 2.4.2 Tumor-Specific Antigens; 2.5 Uptake by Cells & Drug Release; 2.6 Tumor Environment & Drug Access; 2.7 Drug Payload; 2.8 A Word of Caution; 2.9 Conclusions; References; Part II: EPR Effect and ECM Modification. Chapter 3: Extracellular Matrix Degrading Enzymes for Nanocarrier-Based Anticancer Therapy; 3.1 Matrix in Tumors; 3.2 Hyaluronic Acid; 3.2.1 HA in Tumors; 3.2.2 Physico-Chemical Properties of Hyaluronic Acid; 3.2.3 Hyaluronidase; 3.2.4 Hyaluronidase as an Adjuvant; 3.2.5 Hyaluronidase for Nanocarrier Based Anti-Cancer Therapy; 3.2.6 Immobilized Hyaluronidase for Nanocarrier Based Anti-Cancer Therapy; 3.2.7 Safety and Clinical Trials with Human Recombinant Hyaluronidase; 3.3 Collagen and Collagenase; 3.3.1 Collagen in Cancer; 3.3.2 Collagenase for Nanocarrier Based Anti-Cancer Therapy. 3.4 Chondroitin Sulfate Proteoglycans (CSPGs); 3.4.1 CSPGs in Cancer; 3.4.2 Chondroitinase in Nanocarrier Based Anticancer Therapy; 3.5 Conclusions and Outlook; References; Chapter 4: Nanocarrier-Based Anticancer Therapies with the Focus on Strategies for Targeting the Tumor Microenvironment; 4.1 Introduction: Tumor Microenvironment; 4.1.1 Angiogenic Blood Vessels; 4.1.2 Lymphatic System and Infiltrating Immune Cells; 4.1.3 Cancer-Associated Fibroblasts (CAF); 4.1.4 Non-cellular Components; 4.2 Characteristics to be Considered to Design Nanoparticles Targeting Tumor Microenvironment. 4.2.1 Geometry; 4.2.1.1 Size; 4.2.1.2 Shape; 4.2.2 Surface Charge; 4.2.3 pH; 4.2.4 Modifications of Nanocarriers; 4.2.4.1 NP Modification for Targeting; 4.2.4.2 NP Modification to Avoid Mononuclear Phagocyte System MPS Clearance; 4.2.4.3 NP Modification for Intracellular Fate Modulation; 4.3 Nanovectors Targeting Tumor Microenvironment; 4.3.1 Vasculature; 4.3.1.1 Angiogenesis; 4.3.1.2 Hypoxia; 4.3.2 Immune and Lymphatic Cells; 4.3.3 CAF; 4.3.4 ECM; 4.4 Conclusion and Perspectives; References; Part III: How to Extend the Circulation Time of Nanovehicles.
• Publisher Details: Cham, Switzerland : Springer
• Publication Date: 2016
• Extent: 1 online resource
• Subjects: 615/.6; Medicine; Drug delivery systems; Nanomedicine; MEDICAL -- Pharmacology; Drug delivery systems; Nanomedicine; Biomedicine; Biomedicine general; Nanotechnology; Technology & Engineering -- Nanotechnology & MEMS; Nanotechnology; Nanotechnology; Medical -- General; Medical research; Electronic books
• Languages: English
• ISBNs: 9783319435251; 3319435256; 9783319435237
• Related ISBNs: 331943523X; 9783319435237
• Notes: Note: Includes bibliographical references at the end of each chapters and index.
• Access Rights: Legal Deposit; Only available on premises controlled by the deposit library and to one user at any one time; The Legal Deposit Libraries (Non-Print Works) Regulations (UK).
• Access Usage: Restricted: Printing from this resource is governed by The Legal Deposit Libraries (Non-Print Works) Regulations (UK) and UK copyright law currently in force.